The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.
 
Sahil Doshi
No Relationships to Disclose
 
Andrea Lopez Sanmiguel
No Relationships to Disclose
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Ritesh Kotecha
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc
Research Funding - Allogene Therapeutics (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst)
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis; HiberCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Marie Carlo
Honoraria - OncLive/MJH Life Sciences; OncLive/MJH Life Sciences
Other Relationship - Kidney Cancer Association; Prostate Cancer Foundation; Robert Wood Johnson Foundation
 
Darren Feldman
Consulting or Advisory Role - BioNTech; Debiopharm Group; Exelixis; Renibus Therapeutics; Telix Pharmaceuticals; Xencor
Research Funding - Bristol-Myers Squibb/Roche; Decibel Therapeutics (Inst); Exelixis; Telix Pharmaceuticals
Other Relationship - UpToDate
 
Robert Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Martin Voss
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Merck; Oncorena
Research Funding - Exelixis; Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; BMS; Genentech/Roche; NiKang Therapeutics